Eli Lilly and Company’s (LLY) human pharmaceutical segment includes oncology products, including Alimta, Erbitux, Cyramza, and Portrazza. For 3Q17, the portfolio reported a decline in revenues due to lower sales for Alimta, Portrazza, and Erbitux, partially offset by strong sales for Cyramza.
The above chart shows revenues for Eli Lilly’s key oncology products over the last eight quarters.
Alimta is a blockbuster chemotherapy drug in Eli Lilly’s oncology portfolio. It had revenues of $514.5 million in 3Q17, a 10% decline compared to $570 million in 3Q16. The decline was driven by lower US and international sales, partially offset by a positive impact of foreign exchange. US sales fell 6%, and international sales fell 14%.
Erbitux is an oncology drug for the treatment of metastatic colorectal cancer and head and neck cancer. Erbitux reported revenues of $163 million in 3Q17, an 11% decline compared to $185 million in 3Q16. The decline in revenues was driven by lower US and international sales and a 2% negative impact of foreign exchange. US sales declined 12%, while international sales declined 8%.
Other oncology products
Eli Lilly’s other oncology drugs include Cyramza and Portrazza. Cyramza reported revenues of $196 million in 3Q17, an increase of 23% compared to $159 million in 3Q16. Growth was driven by an increase in US and international sales. US sales increased 4%, and international sales increased 38%.
Portrazza reported revenues of $2.3 million in 3Q17, a decline of 57% compared to 3Q16.